Interesting Images68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate CancerSchollhammer, Romain MD∗; de Clermont Gallerande, Henri MD∗; Robert, Grégoire MD, PhD†; Yacoub, Mokrane MD‡; Vimont, Delphine MSc∗; Hindié, Elif MD, PhD∗; Fernandez, Philippe MD, PhD∗; Morgat, Clément PharmD, PhD∗ Author Information From the ∗Nuclear Medicine Department, University Hospital of Bordeaux and INCIA, University of Bordeaux Departments of †Urology ‡Pathology, University Hospital of Bordeaux, Bordeaux, France. Received for publication January 3, 2019; revision accepted May 3, 2019. Conflict of interest and sources of funding: This study was funded by the University Hospital of Bordeaux under grant AOI 2016 and was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57. None declared to all authors. Correspondence to: Clément Morgat, PharmD, PhD, Nuclear Medicine Department, University Hospital of Bordeaux, Place Amélie Raba Léon, 33076 Bordeaux, France. E-mail: [email protected]. Clinical Nuclear Medicine: September 2019 - Volume 44 - Issue 9 - p e535-e536 doi: 10.1097/RLU.0000000000002672 Buy Metrics Abstract 68Ga-labeled prostate-specific membrane antigen inhibitors and 68Ga-labeled gastrin-releasing peptide receptor antagonists showed interesting results for staging biochemically recurrent prostate cancer. In this case, 68Ga–prostate-specific membrane antigen-617 PET/CT, 68Ga-RM2 PET/CT, and 18F-choline PET/CT were performed in a patient (66-year-old man, prostate-specific antigen = 6.7 ng/mL) with biopsy-proven Gleason 9 (5 + 4) prostate cancer, candidate for radical prostatectomy and lymph node dissection. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.